Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines ...

Genentech sues federal government over 340B discounts to STD clinics, joining Amgen, Eli Lilly and UCB in challenging program ...

Metsera and Maze Therapeutics priced their Nasdaq IPOs, raising $275M and $140M respectively. Both companies backed by ARCH ...

Daiichi Sankyo promoted Hiroyuki Okuzawa to CEO, and he will take over from Sunao Manabe on April 1. Okuzawa is currently ...

NHS England & Vertex reach deal for sickle cell gene therapy Casgevy, making it available at an undisclosed reduced price ...

AstraZeneca has canceled its plans to expand its vaccine manufacturing site in Speke, UK, after the new UK government trimmed ...

Merck announced Thursday that it prematurely stopped a Phase 3 study of Winrevair, a drug approved last year for a rare form ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP ...

FDA expands Ozempic label to include kidney disease benefits in type 2 diabetes patients. Novo Nordisk's drug can now be ...

Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson ...

Maze Therapeutics is eyeing a $113 million initial public offering a little under two months after revealing a $115 million ...

VC, a venture capital firm that has spread its bets across multiple industries, including biotech and digital health, is ...